08/05/2026
The EU is currently facing security challenges in a context of international instability. Among these are rising Chemical, Biological, Radiological, and Nuclear (CBRN) threats. To enhance , it is crucial to develop medical countermeasures (MCMs) to protect both military and civilian populations. To address this gap, the RESILIENCE Framework Partnership Agreement was established in 2022, providing a multi-annual action plan to strengthen European MCM research based on three pillars: i) , ii) Prevention & iii) Prophylaxis and Treatment.
RESILIENCE-R-2025 is the third research action under this plan. It is composed of 4 sub-projects: i) DIAG BACT-Lab and Point of Care (POC) diagnosis of bacterial agents ; ii) AG-TEST-B-Next generation of antigenic and genetic tests for Biological (B) agents; iii) ANTIVIR-Antiviral medical countermeasures usable in an operational field, and iv) VECT-Advanced strategies for the administration and vectorization of Medical Counter measurements (MCM) against nerve agents. The action involves collaborations among 16 organizations from nine EU countries, including military, academic and industrial partners. The ultimate goal is to develop new MCM against chemical and biological threats that fulfil military operational and functional requirements. Diagnostic devices prototypes will be developed for the detection of highly risk pathogens. They include three technologies deployable on the field, i.e. next generation assays, Loop-mediated isothermal amplification, a breath analyser, and one detection device deployable in mobile labs, based on compact sequencing. The project will lead those innovative MCM candidates to TRL 4-5.
In the photo, some members of the subproject AG-TEST-B during the project kick-off meeting in Paris, including (from our group) Prof. Arben Merkoçi, Dr. Andrew Piper, Dr. Daniel Quesada Gonzàlez and MSc Carmine Andrea Esposito.
